USE OF PULSED RADIO FREQUENCY

• US 20130079835A1
• Filed: 12/23/2010
• Published: 03/28/2013
• Est. Priority Date: 12/23/2009
• Status: Active Grant

• Current Assignee: Hitops GmbH
• Original Assignee: Hitops GmbH
• Inventors: Teixeira, Alexandre Jose Leonardo, Sluijter, Menno Emanuel
• Granted Patent: US 9,162,075 B2
• Time in Patent Office: Days
• US Class Current: 607/3
• CPC Class Codes: A61N 1/056 Transvascular endocardial electrode systems
• CPC Class Codes: A61N 1/06 for high-frequency therapy
• CPC Class Codes: A61N 1/40 Applying electric fields by inductive or capacitive coupling microwave apparatus A61N5/00; Applying radio-frequency signals
• CPC Class Codes: A61N 5/00 Radiation therapy ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00

Abstract

The invention relates to a method for medical treatment of a mammal, preferably a human, by applying pulsed radiofrequency (PRF) stimulation intravascularly. More particularly, said method has as effect that it boosts the immune system and/or that it relieves pain. In a preferred embodiment, the disease or condition to be treated is caused or accompanied by immunodeficiency, more preferably the disease or condition is selected from the group of cancer, infectious diseases, immunosuppression or otherwise caused immunodeficiencies. Also auto- immune diseases and conditions associated with allostatic load are preferred for treatment with the method of the invention. In an also preferred embodiment, the PRF stimulation is applied together with vaccination.

Claims

1. A method for medical treatment of a disease or condition in a mammal, the method comprising applying pulsed radiofrequency (PRF) stimulation intravascularly to the mammal to medically treat the disease or condition.

2. The method according to claim 1, wherein medical treatment is boosting the immune system or relieving pain.

3. The method according to claim 1, wherein the disease or condition to be treated is an inflammation related disease, an immune disease, an auto-immune disease or a disease related to allostatic load.

4. The method according to claim 3, wherein the disease or condition is selected from the group of cancer, infectious diseases, immunosuppression or immunodeficiencies.

5. The method according to claim 3, wherein the disease or condition is selected from the group of infectious diseases, in particular viral infections, and more specifically HIV infection;

cancer, comprising solid tumours and blood borne tumours, such as lymphoma'"'"'s, myeloma'"'"'s, leukemia, breast cancer, lung cancer, head-and-neck cancers, colon cancer, pancreas cancer, prostate cancer, gastric cancer, ovarian cancer, and metastases thereof;

immunosuppression, caused by chemotherapy, radiation therapy, or treatment with corticosteroids;

immunodeficiency, e.g. caused by malnutrition, ageing, cancer, viral infections or (hereditary) primary immunodeficiencies like SCID, ADA deficiency, Di George'"'"'s syndrome, Omenn syndrome, agammaglobulinemia, Wiskott-Aldrich syndrome, ataxia telangiectasia, ataxia-like syndrome, Nijmegen breakage syndrome, Bloom syndrome, etc.;

complement deficiencies; and

phagocyte disorders, such as Kostmann syndrome, neutropenia;

auto-immune diseases, such as rheumatoid arthritis, alopecia areata, ankylosing sponmdylitis, autoimmune cardiopathy, autoimmune hepatitis, autoimmune pancreatitis, autoimmune inner ear disease, autoimmune progesterone dermatitis, autoimmune uveitis, Chagas disease, chronic obstructive pulmonary disease (COPD), celiac disease, cold agglutinin disease, Crohn'"'"'s disease, dermatomyositis, diabetes mellitus, eosinophilic fasciitis, gastrointestinal pemphigoid, Goodpasture'"'"'s syndrome, Graves'"'"' disease, Guillain-Barré

syndrome, Hashimoto'"'"'s encephalitis, Hashimoto'"'"'s thyroiditis, thrombocytopenic purpura, irritable bowel syndrome (IBS), Kawasaki'"'"'s disease, lupus erythematosus, Miller-Fisher syndrome, mixed connective tissue disease (MCTD), morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia, osteoporosis, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, inflammatory neuropathy, psoriasis, psoriatric arthritis, relapsing polychondritis, restless leg syndrome, sarcoidosis, schizophrenia, giant cell arthritis, ulcerative colitis, vaculitis, vitiligo, Wegner'"'"'s granulomatosis; and

conditions related to allostatic load like insulin resistance, metabolic syndrome, diabetes type 2, atherosclerosis, hypertension, coronary infarction, stroke, arthrosis, migraine, cognitive dysfunctions;

stress related allostatic load conditions, such as depression, burn-out, chronic fatigue syndrome, fibromyalgia, post-traumatic stress syndrome, stress related sleep disorders, gastric ulcers; and

trauma related allostatic load conditions, such as post-traumatic vegetative syndromes, neuropathies, phantom pain and unexplained persistent pain following trauma.

6. The method according to claim 2, wherein PRF is applied together with vaccination.

7. The method according to claim 1, where PRF is given before, simultaneous with or after chemical, radiation or surgical treatment.

13. The method according to claim 1 performed using an active electrode that is an electro-catheter, with or without a steerable tip, to enable placement of the active part of the electrode closer to a target.

14. The method according to claim 13, wherein the target is a tissue, such as a solid tumor or a diseased organ, or wherein the target is the nervus vagus.

15. The method of claim 1 where the mammal is a human.

8. A method of medically treating a mammal, the method comprising administering intravascular pulse radiofrequency (PRF) to the mammal for therapy of the mammal.

9. (canceled)

10. A method for treating immunodeficiency in a mammal, the method comprising administering intravascular pulse radiofrequency (PRF) to the mammal for the treatment of immunodeficiency in the mammal.

11. A method for treating a mammal, the method comprising administering intravascular pulse radiofrequency (PRF) to the mammal for use in the treatment of a disease selected from the group of infectious diseases, in particular viral infections, and more specifically HIV infection;

cancer, comprising solid tumours and blood borne tumours, such as lymphoma'"'"'s, myeloma'"'"'s, leukemia, breast cancer, lung cancer, head-and-neck cancers, colon cancer, pancreas cancer, prostate cancer, gastric cancer, ovarian cancer, and metastases thereof;

immunosuppression, caused by chemotherapy, radiation therapy, or treatment with corticosteroids;

immunodeficiency, e.g. caused by malnutrition, ageing, cancer, viral infections or (hereditary) primary immunodeficiencies like SCID, ADA deficiency, Di George'"'"'s syndrome, Omenn syndrome, agammaglobulinemia, Wiskott-Aldrich syndrome, ataxia telangiectasia, ataxia-like syndrome, Nijmegen breakage syndrome, Bloom syndrome, etc.;

complement deficiencies; and

phagocyte disorders, such as Kostmann syndrome, neutropenia;

auto-immune diseases, such as rheumatoid arthritis, alopecia areata, ankylosing sponmdylitis, autoimmune cardiopathy, autoimmune hepatitis, autoimmune pancreatitis, autoimmune inner ear disease, autoimmune progesterone dermatitis, autoimmune uveitis, Chagas disease, chronic obstructive pulmonary disease (COPD), celiac disease, cold agglutinin disease, Crohn'"'"'s disease, dermatomyositis, diabetes mellitus, eosinophilic fasciitis, gastrointestinal pemphigoid, Goodpasture'"'"'s syndrome, Graves'"'"' disease, Guillain-Barré

syndrome, Hashimoto'"'"'s encephalitis, Hashimoto'"'"'s thyroiditis, thrombocytopenic purpura, irritable bowel syndrome (IBS), Kawasaki'"'"'s disease, lupus erythematosus, Miller-Fisher syndrome, mixed connective tissue disease (MCTD), morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, inflammatory neuropathy, psoriasis, psoriatric arthritis, relapsing polychondritis, restless leg syndrome, sarcoidosis, schizophrenia, giant cell arthritis, ulcerative colitis, vaculitis, vitiligo, Wegner'"'"'s granulomatosis; and

conditions related to allostatic load like insulin resistance, metabolic syndrome, diabetes type 2, atherosclerosis, hypertension, coronary infarction, stroke, arthrosis, migraine, cognitive dysfunctions;

stress related allostatic load conditions, such as depression, burn-out, chronic fatigue syndrome, fibromyalgia, post-traumatic stress syndrome, stress related sleep disorders, gastric ulcers; and

trauma related allostatic load conditions, such as post-traumatic vegetative syndromes, neuropathies, phantom pain and unexplained persistent pain following trauma.

12. An electrical signal consisting of current pulses in a radiofrequency range with a voltage of 10-80 V to be delivered in pulse bursts with a duration of 0.1-100 msec and burst frequency of 1/sec-20/sec to be delivered by an electrode with an impedance of less than 1000Ω

for medical treatment.